Search 

GTN - Transforming drug discovery through interdisciplinary innovation. At GTN, a multidisciplinary, innovation-driven company, we are searching the astronomically large space of drug-like molecules with our unique patented technology, Generative Tensorial Networks. Our software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, discovering molecules entirely hidden from view. This will create substantial efficiencies in the whole drug development cycle.

Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product ‐ Ibuprofen TEPI Patch ‐ entered the clinic in 2018.

Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.

Nanna Therapeutics has built a unique and game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. Utilising its paradigm shift in the speed, efficiency and quality of drug discovery, as well as massively enhancing safety profiling to improve clinical success, Nanna Therapeutics is developing breakthrough medicines for the treatment of diseases that involve defects in mitochondrial function, such as MELAS and LHON, as well as diseases of the central nervous system, such as Parkinson’s, Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS).

The National Institute for Health Research (NIHR) is the most integrated clinical research system in the world, we drive research from bench to bedside for the benefit of patients and the economy under a number of themes by: - transforming research in the NHS - increasing the volume of applied health research for the benefit of patients and the public - driving faster translation of basic science discoveries into tangible benefits - developing and supporting the people who conduct and contribute to applied health research - attracting investment by the life sciences industry through our world-class facilities for health research.

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology.

The idea is straightforward – to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells – awakening previously defunct or dormant cellular processes.

Therakind, a private European pharmaceutical company, is focused on creating and developing safe, effective, authorised paediatric and speciality niche medicines. Our primary objective is to increase the availability of authorised paediatric and niche medicines and to ensure that the medication used today is both safe and effective.

Therakind's team has extensive experience in the paediatric pharmaceutical sector, we have the expertise to design clinical programmes and regulatory strategy to advance medicines from concept through to regulatory approval.